Skip to main content

ARCH Venture Partners — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

236
Companies
$22.6B
Total invested
$122.9M
Avg. check
22
Industries
Biotechnology 18Health Care 12Therapeutics 10Medical 10Pharmaceutical 7Life Science 6+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 236
Faraday Pharmaceuticals
November 2022

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.

Biotechnology · Seattle$52.8M Series C
Synchron
November 2025

Synchron is a bioelectronics medicine company that develops neuromodulation solutions for previously-untreatable nervous system conditions.

Information Technology · Brooklyn$200.0M Series D
Elephas
November 2025

Elephas harnesses latest advances in cancer biology, multimodal microscopy, and artificial intelligence to empower clinical decision-making.

Artificial Intelligence (AI) · Madison$40.0M Venture - Series Unknown
Be Biopharma
January 2025

Be Biopharma develops engineered B cell medicines for serious genetic diseases.

Biopharma · Cambridge$92.0M Series C
hC Bioscience
November 2022

HC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.

Biotechnology · Cambridge$16.0M Series A
Sonoma Biotherapeutics
November 2025

Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.

Biotechnology · South San Francisco$300K Grant
Verve Therapeutics
November 2023

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Biotechnology · Boston$143.8M Post-IPO Equity
Soufflé Therapeutics
January 2025

Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.

Biopharma · Watertown$200.0M Series A
Mirador Therapeutics
January 2026

Mirador Therapeutics develops precision medicines for immune-mediated diseases.

Biotechnology · San Diego$250.0M Series B
Aspen Neuroscience
November 2025

Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies and autologous regenerative medicine.

Biotechnology · San Diego$115.0M Series C
Lifordi Immunotherapeutics
November 2025

Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.

Biotechnology · Burlington$42.0M Venture - Series Unknown
Gate Bioscience
November 2025

Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.

Biotechnology · Brisbane$65.0M Series B
Metsera
November 2024

Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.

Biopharma · New York$215.0M Series B
908 Devices
November 2021

908devices manufactures battery-operated, hand-held chemical detection tools used in mass spectrometry.

Battery · Boston$101.0M Post-IPO Equity
Rhygaze
January 2025

Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.

Biotechnology · Basel$86.0M Series A
Resilience
October 2025

Resilience is a biomanufacturing company that provides access to complex medicines and protects biopharmaceutical supply chains.

Biopharma · La Jolla$825.0M Debt Financing
Grail
October 2025

Grail is a healthcare company that develops pan-cancer screening tests designed to detect cancers at an early stage.

Biotechnology · Menlo Park$325.0M Post-IPO Equity
Pelage Pharmaceuticals
October 2025

Pelage Pharma is a regenerative medicine biotechnology company developing treatments for hair loss.

Health Care · Los Angeles$120.0M Series B
Walden Biosciences
October 2023

Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease.

Biotechnology · CambridgeSeries B
Atlas Data Storage
March 2026

Atlas Data Storage is an information technology company focused on data storage solutions.

Database · South San FranciscoSeed
Seaport Therapeutics
March 2026

Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.

Biopharma · Boston$15.0M Grant
Salma Health
February 2026

Salma Health is a concierge neurocognitive clinic that uses neurology and psychiatry techniques to solve various brain conditions.

Health Care · La Jolla$80.0M Series A
Beam Therapeutics
February 2026

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Biotechnology · Cambridge$100.0M Post Ipo Debt
Syndex Bio
February 2026

Syndex Bio is a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease.

Artificial Intelligence (AI) · Cambridge$15.5M Seed

Where ARCH Venture Partners invests

Biotechnology18
Health Care12
Therapeutics10
Medical10
Pharmaceutical7
Life Science6

About ARCH Venture Partners's portfolio

How many companies has ARCH Venture Partners invested in?

ARCH Venture Partners has invested in 236 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does ARCH Venture Partners invest in?

ARCH Venture Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 22 different industry categories.

What is ARCH Venture Partners's largest investment?

Among tracked funding rounds, Resilience received $825.0M in a Debt Financing round. ARCH Venture Partners's total known invested capital is $22.6B.

What is the average investment size for ARCH Venture Partners?

ARCH Venture Partners's average investment size is $122.9M across its portfolio of 236 companies.

What are ARCH Venture Partners's most recent investments?

Recent ARCH Venture Partners portfolio additions include Faraday Pharmaceuticals, Synchron, Elephas, Be Biopharma, hC Bioscience. These companies were founded in 2020 or later.

Reach the founders behind these 236 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →